

## AMENDMENTS TO THE CLAIMS

1-19. (canceled)

20. (previously presented) A method of inhibiting angiogenesis in a target tissue comprising the step of administering  $\alpha$ -Corticotropin Releasing Factor Receptor 2 (CRFR2) agonist to said target tissue, wherein said CRFR2 agonist inhibits angiogenesis in said tissue.

21. (previously presented) The method of claim 20 wherein said CRFR2 agonist is selected from the group consisting of urocortin and corticotropin releasing factor.

22. (original) The method of claim 20, wherein said tissue is selected from the group consisting of heart, brain, pituitary, gonad, kidney, adipose, and gastrointestinal tract tissues.

23. (original) The method of claim 20 wherein said angiogenesis is inhibited in an individual having a

pathophysiological condition selected from the group consisting of cancer and diabetic retinopathy.

24-27. (canceled)